基本信息
文件名称:Eltrombopag-d3-SB-497115-d-sub-3-sub-生命科学试剂-MCE.pdf
文件大小:659.62 KB
总页数:2 页
更新时间:2025-05-23
总字数:约3.47千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Eltrombopag-d3

Cat.No.:HY-W713365

CASNo.:1133710-20-9

Synonyms:SB-497115-d3

分?式:C??H??D?N?O?

分?量:445.49

作?靶点:Isotope-LabeledCompounds;ThrombopoietinReceptor;

Apoptosis;Bacterial

作?通路:Others;Immunology/Inflammation;Apoptosis;Anti-infection

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Eltrombopag-d3(SB-497115-d3)是氘代标记的Eltrombopag.Eltrombopag(SB-497115)是?种具有?服活

性的thrombopoietin-receptor?肽激动剂。Eltrombopag可促??板的活性,?于研究??板计数低的慢性

免疫性??板减少症。Eltrombopag可?于??管的研究。Eltrombopag对多药耐药的?黄?葡萄球菌(

Staphylococcusaureus)也有很强的抑制作?。Eltrombopag还可诱导肝癌细胞凋亡(apoptosis)。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubstitutiononthePharmacokineticsofPharmaceuticals.AnnPharmacother.2019;53(2):211-

216.

[2].Erickson-MillerCL,etal.Preclinicalactivityo